Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained

Wall Street analysts have issued new ratings for biopharma companies, with Gilead receiving a 'Buy' recommendation, Amgen a 'Hold', and ORIC gaining a vote of confidence.